Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Latest Information Update: 23 Mar 2026
At a glance
- Drugs Tirzepatide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms SURMOUNT-1
- Sponsors Hudson Biotech
Most Recent Events
- 23 Mar 2026 New trial record